A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimen
Latest Information Update: 04 Dec 2020
At a glance
- Drugs Everolimus (Primary)
- Indications Adenocarcinoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NECTOR
- 02 Dec 2020 Status changed from active, no longer recruiting to completed.
- 08 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2014 New trial record